Fig. 3

Targeted therapy using 033 T PDX cells. a In vitro sensitivity of primary PDX cells (033 T) and normal lung tissues to a panel of targeted therapeutic agents. Primary PDX cells were cultured from the established xenograft tumors in serum-free sphere culture conditions. Dose response curves for the 3 molecular targeted agents, such as neratinib, canertinib, and crizotinib. b Treatment with MET inhibitor, crizotinib impaired tumor sphere formation in 033 T cell cultures. c Treatment with crizotinib significantly inhibited cell proliferation of 033 T cells from day 5 onward. d Protein analysis of 033 T cells by western blot showed a reduction of phosphorylated MET and downstream components of MET signaling pathway, such as STAT3 and ERK1/2, following the treatment with MET inhibitor, crizotinib